About La Jolla Pharmaceutical
La Jolla Pharmaceutical is a company based in San Diego (United States) founded in 1989 was acquired by Innoviva in July 2022.. The company has 71 employees as of December 31, 2022. La Jolla Pharmaceutical has completed 1 acquisition, including Tetraphase Pharmaceuticals. La Jolla Pharmaceutical offers products and services including GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN. La Jolla Pharmaceutical operates in a competitive market with competitors including Freeline, Disc Medicine, Keros Therapeutics, Jasper Therapeutics and Interius Biotherapeutics, among others.
- Headquarter San Diego, United States
- Employees 71 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Innoviva, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of La Jolla Pharmaceutical
La Jolla Pharmaceutical offers a comprehensive portfolio of products and services, including GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for critical care conditions in patients.
Therapy for infectious diseases caused by bacteria.
Treatment for drug-resistant microorganisms.
Investigational therapy for gonorrhea infections.
Unlock access to complete
Unlock access to complete
Funding Insights of La Jolla Pharmaceutical
- Total Funding Total Funding
- Total Rounds 3
- Last Round Debt – Conventional — $125.0M
-
First Round
First Round
(18 Apr 2011)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2018 | Amount | Debt – Conventional - La Jolla Pharmaceutical | Valuation |
investors |
|
| Oct, 2013 | Amount | Post-IPO - La Jolla Pharmaceutical | Valuation |
investors |
|
| Apr, 2011 | Amount | Post-IPO - La Jolla Pharmaceutical | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in La Jolla Pharmaceutical
La Jolla Pharmaceutical has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Innoviva and HealthCare Royalty Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare royalty investments are focused on US and UK markets.
|
Founded Year | Domain | Location | |
|
Respiratory prescription drugs are developed and in-licensed for COPD treatment.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by La Jolla Pharmaceutical
La Jolla Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tetraphase Pharmaceuticals. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Tetracycline analogs are developed for multidrug-resistant bacterial infections.
|
2006 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - La Jolla Pharmaceutical
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
La Jolla Pharmaceutical Comparisons
Competitors of La Jolla Pharmaceutical
La Jolla Pharmaceutical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Freeline, Disc Medicine, Keros Therapeutics, Jasper Therapeutics and Interius Biotherapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of hematologic diseases
|
|
| domain | founded_year | HQ Location |
Small molecules are developed to treat hematologic and musculoskeletal disorders.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating multiple diseases
|
|
| domain | founded_year | HQ Location |
Cancer therapeutics are developed using targeted gene editing platforms.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on La Jolla Pharmaceutical
Frequently Asked Questions about La Jolla Pharmaceutical
When was La Jolla Pharmaceutical founded?
La Jolla Pharmaceutical was founded in 1989 and raised its 1st funding round 22 years after it was founded.
Where is La Jolla Pharmaceutical located?
La Jolla Pharmaceutical is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of La Jolla Pharmaceutical?
Larry Edwards is the current CEO of La Jolla Pharmaceutical.
How many employees does La Jolla Pharmaceutical have?
As of Dec 31, 2022, the latest employee count at La Jolla Pharmaceutical is 71.
What is the annual revenue of La Jolla Pharmaceutical?
Annual revenue of La Jolla Pharmaceutical is $75.72M as on Dec 31, 2021.
What does La Jolla Pharmaceutical do?
La Jolla Pharmaceutical is developing therapies for treating life-threatening diseases. The companys lead product candidate, LJPC-401 is its a formulation of synthetic human hepcidin (peptide hormones) for the potential treatment of hemochromatosis, and beta thalassemia. Its in phase II clinical trials. Other candidates of the company include LJPC-30Sa and LJPC-30Sb, are next-generation gentamicin derivatives for the treatment of bacterial infections and rare genetic disorders, LJPC-501 is its proprietary formulation of angiotensin II for treating catecholamine-resistant hypotension and hepatorenal syndrome.
Who are the top competitors of La Jolla Pharmaceutical?
La Jolla Pharmaceutical's top competitors include Keros Therapeutics, Disc Medicine and Freeline.
What products or services does La Jolla Pharmaceutical offer?
La Jolla Pharmaceutical offers GIAPREZA, XERAVA, XACDURO, and ZOLIFLODACIN.
How many acquisitions has La Jolla Pharmaceutical made?
La Jolla Pharmaceutical has made 1 acquisition, including Tetraphase Pharmaceuticals.
Who are La Jolla Pharmaceutical's investors?
La Jolla Pharmaceutical has 2 investors. Key investors include Innoviva, and HealthCare Royalty Partners.